MAPT and dementia: Specifically, three Aβ peptides (Aβ38, Aβ40, and Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) were analyzed in patients diagnosed with clinical dementia, MCI, and subjective cognitive decline (SCD), as well as in a control group [129] (Table 1).